IDEXX Laboratories beats Q1 estimates on top and bottom line, increases outlook
IDEXX Laboratories press release  (NASDAQ:IDXX): Q1  GAAP EPS of $2.55  beats by $0.17.
Revenue of $900M (+7.6% Y/Y)  beats by $9.4M.
Increases 2023 revenue guidance to $3,615 million - $3,700 million, reflecting 7.5% - 10% growth as reported and organically. (consensus $3.66B)
Updates 2023 EPS outlook to $9.33 - $9.75, a year-over-year increase of 16% - 22% as reported and 20% - 26% on a comparable basis, including ~12% combined growth benefit from a customer contract resolution payment in Q1 2023 and lapping of discrete 2022 R&D investments. (vs. consensus EPS of $9.63)